866-997-4948(US-Canada Toll Free)

Essential Tremor - Pipeline Review, H2 2016

Published By :

Global Markets Direct

Published Date : Dec 2016

Category :

Pharmaceutical

No. of Pages : 48 Pages

Essential Tremor - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Essential Tremor Pipeline Review, H2 2016, provides an overview of the Essential Tremor (Central Nervous System) pipeline landscape.

Essential tremor is a type of involuntary shaking movement in which no cause can be identified. Involuntary means you shake without trying to do so. Essential tremor is the most common type of tremor. The exact cause for essential tremor is unknown. Tremors occur when there is a problem with the nerves that supply certain muscles. The tremor is more likely to be noticed in the hands, but may affect the arms, head, eyelids, or other muscles. The tremor rarely affects the legs or feet. Treatment may not be needed unless the tremors interfere with your daily activities or cause embarrassment.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Essential Tremor Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Essential Tremor (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Essential Tremor (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Essential Tremor and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Discovery stages are 2, 2 and 2 respectively.Essential Tremor.

Essential Tremor (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Essential Tremor (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Essential Tremor (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Essential Tremor (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Essential Tremor (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Essential Tremor (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Essential Tremor (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Essential Tremor (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Essential Tremor Overview 6
Therapeutics Development 7
Pipeline Products for Essential Tremor - Overview 7
Essential Tremor - Therapeutics under Development by Companies 8
Essential Tremor - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Essential Tremor - Products under Development by Companies 11
Essential Tremor - Companies Involved in Therapeutics Development 12
Merz Pharma GmbH & Co KgaA 12
Neurocrine Biosciences Inc 13
Sage Therapeutics Inc 14
Essential Tremor - Therapeutics Assessment 15
Assessment by Monotherapy Products 15
Assessment by Target 16
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
incobotulinumtoxin A - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
NBI-640756 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
SAGE-217 - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
sepranolone - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
Small Molecules to Antagonize GPCR for Central Nervous System Diseases - Drug Profile 38
Product Description 38
Mechanism Of Action 38
R&D Progress 38
Small Molecules to Target Ion Channels for CNS Disorders - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
Essential Tremor - Dormant Projects 40
Essential Tremor - Discontinued Products 41
Essential Tremor - Product Development Milestones 42
Featured News & Press Releases 42
Apr 17, 2016: Sage Therapeutics Expands Scientific, Clinical and Burden of Illness Data for SAGE-547 in SRSE and Essential Tremor at the 2016 American Academy of Neurology Annual Meeting 42
Nov 04, 2015: Neurocrine Biosciences Announces Expansion of its Clinical Pipeline 43
Sep 03, 2015: SAGE Therapeutics Announces Results From Successful Exploratory Trial in Essential Tremor 44
Oct 23, 2014: SAGE Therapeutics Initiates Exploratory Study of SAGE-547 in Essential Tremor 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables
Number of Products under Development for Essential Tremor, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Comparative Analysis by Early Stage Development, H2 2016 10
Products under Development by Companies, H2 2016 11
Essential Tremor - Pipeline by Merz Pharma GmbH & Co KgaA, H2 2016 12
Essential Tremor - Pipeline by Neurocrine Biosciences Inc, H2 2016 13
Essential Tremor - Pipeline by Sage Therapeutics Inc, H2 2016 14
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Stage and Target, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Essential Tremor - Dormant Projects, H2 2016 40
Essential Tremor - Discontinued Products, H2 2016 41

List of Figures
Number of Products under Development for Essential Tremor, H2 2016 7
Number of Products under Development by Companies, H2 2016 8
Comparative Analysis by Clinical Stage Development, H2 2016 9
Assessment by Monotherapy Products, H2 2016 15
Number of Products by Targets, H2 2016 16
Number of Products by Stage and Targets, H2 2016 16
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Types, H2 2016 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *